超低剂量CT肾结石监测减少超声与X线使用:多学科质量改进
本研究通过六西格玛框架分析肾结石监测影像使用,实施锡滤过超低剂量CT方案。ULD CT平均辐射剂量较标准低剂量非增强CT降低66%(5→1.7 mSv);持续采用期超声中位使用从35次/月降至10次/月(P=.002),KUB从15.0降至4.0(P=.005),ULD CT从0增至43.5(P<.001)。Medicare允许费用超声+KUB为133.59美元,ULD CT为180.82美元,绝对差47.23美元。
要点
- ULD CT辐射剂量较标准低剂量非增强CT平均降低66%,由5 mSv降至1.7 mSv。
- 持续采用期超声中位使用从35次/月降至10次/月(P=.002),KUB从15.0降至4.0(P=.005)。
- Medicare允许费用中超声+KUB为133.59美元,ULD CT为180.82美元,绝对差47.23美元。
核心结论
- 实施超低剂量CT方案可标准化肾结石监测,显著减少超声和KUB检查使用。
- ULD CT较联合超声+KUB的Medicare允许费用绝对差为47.23美元,费用差仅轻度增加。
- 结果支持更广泛采用ULD CT,并与更新的国家指南保持一致。
研究设计与样本
- 多学科质量改进研究,采用六西格玛定义-测量-分析-改进-控制框架。
- 分基线、实施、持续采用三阶段监测影像使用与费用。
- 干预包括引入锡滤过超低剂量CT方案并推荐CT用于肾结石监测。
- 剂量比较对象为标准低剂量非增强CT。
诊断标准与关键数值
- ULD CT平均辐射剂量从5 mSv降至1.7 mSv,较标准低剂量非增强CT降低66%。
- 持续采用期超声中位使用从35次/月(IQR 30-36)降至10次/月(IQR 8.5-18),降幅71.4%(P = .002)。
- 持续采用期KUB中位使用从15.0次/月(IQR 9-19)降至4.0次/月(IQR 3-5.5)(P = .005)。
- 持续采用期ULD CT中位使用从0次/月(IQR 0-0)增至43.5次/月(IQR 32.5-58.5)(P < .001)。
- Medicare全球费用:联合超声+KUB为133.59美元,ULD CT为180.82美元,绝对差47.23美元。
临床应用与阅片要点
- 肾结石监测可优先考虑ULD CT,以减少超声和KUB分开预约的多次就诊。
- 报告可标注为超低剂量CT监测方案,便于追踪辐射剂量和费用。
- 需注意ULD CT的Medicare允许费用比超声+KUB联合高47.23美元,但未计两次就诊协调成本。
- 向临床沟通辐射剂量降低66%,有助于缓解对CT辐射的顾虑。
局限性
- 费用比较未计入超声和KUB两次就诊可能带来的额外时间与协调成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Renal stone surveillance often relies on ultrasound and radiography of the kidney, ureter, and bladder (KUB) because of concerns about CT radiation and cost, despite CT's superior accuracy. Limited awareness and accessibility of ultra-low-dose (ULD) CT contributes to underuse. The aim of this study was to reduce ultrasound use for renal stone monitoring by 30%, with KUB tracked secondarily, without increasing Medicare-allowed amount through the implementation of a ULD CT protocol.
METHODS: Using the Six Sigma define, measure, analyze, improve, and control framework, a multidisciplinary team analyzed baseline imaging patterns and identified key drivers of ultrasound and KUB overuse: radiation concerns and lack of awareness and accessibility. Interventions included incorporating a tin-filter ULD CT protocol and recommending CT for surveillance imaging. Imaging utilization and costs were monitored in three phases (baseline, implementation, and sustained adoption).
RESULTS: Implementation of the ULD CT protocol reduced mean radiation dose by 66% (from 5 to 1.7 mSv) compared with standard low-dose noncontrast CT. Compared with the baseline, in the sustained adoption phase, ultrasound utilization decreased from a median of 35 examinations per month (interquartile range [IQR], 30-36) to 10 examinations per month (IQR, 8.5-18), representing a 71.4% reduction (P = .002); KUB utilization decreased from a median of 15.0 examinations per month (IQR, 9-19) to 4.0 examinations per month (IQR, 3-5.5) (P = .005); and ULD CT increased from a median of 0 examinations per month (IQR, 0-0) to 43.5 examinations per month (IQR, 32.5-58.5) (P < .001). The Medicare global fee for combined ultrasound and KUB was $133.59 compared with $180.82 for ULD CT, an absolute difference of $47.23, not accounting for potential additional time and coordination associated with two radiology visits for ultrasound- and KUB-based surveillance.
CONCLUSIONS: Implementing ULD CT standardized renal stone surveillance reduced ultrasound and KUB use but had a modest increase in cost difference in Medicare-allowed amount. Findings support the broader adoption of ULD CT and aligning with updated national guidelines.
引用
- Ponce, Zulfiqar, Stern, et al. Implementation of Ultra-Low-Dose CT for Renal Stone Surveillance Was Associated With Reduced Ultrasound and Radiography Use: A Multidisciplinary Quality Improvement Initiative. J Am Coll Radiol. 2026. PMID: 42637066. doi:10.1016/j.jacr.2026.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。